Lumiradx announces new investment for ongoing development of its point of care molecular tuberculosis test

Company receives $14.2m in grants from the bill & melinda gates foundation to support the tb test's ongoing development and future launch into developing countries company receives $14.2m in grants from the bill & melinda gates foundation to support the tb test's ongoing development and future launch into developing countries
LMDX Ratings Summary
LMDX Quant Ranking